Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Response of prostate cancer to addition of dutasteride after progression on abiraterone.

ABSTRACT:

SUBMITTER: Lian JP

PROVIDER: S-EPMC7991817 | biostudies-literature | 2021 Mar-Apr

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Response of prostate cancer to addition of dutasteride after progression on abiraterone.

Lian Jian-Po JP Gao Yuan-Yuan YY Tang Jing-Jie JJ Chen Xi X Liu Ying Y Wu Deng-Long DL Li Zhen-Fei ZF Huang Sheng-Song SS

Asian journal of andrology 20210301 2

PMID: 32896838

Similar Datasets

A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.

Project description: Not available

| S-EPMC5315609 | biostudies-literature

Abiraterone resistance in prostate cancer cells

Project description:Castration resistant prostate cancer (CRPC) develops resistance to antiandrogens affecting Androgen Receptor (AR) signaling through a variety of mechanism. Because of this, the efficacy of androgen receptor targeted therapy remains limited for many patients with CRPC. We developed C42B-Abiraterone (Abi) and resistance cells to study changes in transcriptomic profile compared to parental cells.

2023-01-01 | GSE220467 | GEO

Plasma AR and abiraterone-resistant prostate cancer.

Project description: Not available

| S-EPMC6112410 | biostudies-literature

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer.

Project description: Not available

| S-EPMC9578325 | biostudies-literature

Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.

Project description: Not available

| S-EPMC11695152 | biostudies-literature

Prostate Cancer Gene Expression Changes after Treatment with Neoadjuvant Dutasteride

Project description:To identify molecular changes underlying the chemopreventive or tumor promoting effects of SRD5A inhibition, we profiled gene expression changes in benign prostate epithelium from patients with PCa treated with dutasteride, a dual SRD5A inhibitor. Subjects were aged 45-80 years with clinically localized PCa (T1C to T2b), Gleason score <7, and serum PSA 2.5-10 ng/dL. 81 men were randomized to immediate RP (n=25) or to dutasterdie at 0.5 mg (n=26) or 3.5 mg (n=24) orally per day for four months prior to RP. Prostate samples embedded in OCT were used for laser capture microdissection (LCM). Keywords: clinical trial, Dutasteride, PEDB, dose response, prostate cancer, microarray

2008-12-01 | GSE9972 | GEO

Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.

Project description: Not available

| S-EPMC5824213 | biostudies-literature

Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning.

Project description: Not available

| S-EPMC10082805 | biostudies-literature

The Role of CENPK Splice Variant in Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.

Project description: Not available

| S-EPMC11475995 | biostudies-literature

Abiraterone in metastatic prostate cancer without previous chemotherapy.

Project description: Not available